• Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Featured Page 209

Featured

Latest
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

Q3’25 Psychedelic Drug Development Pipeline: Bullseye Charts

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

August 2025 Psychedelic Patent Update

Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos

Pα+ Psychedelic Bulletin #208: Psychedelic CEOs’ FDA Wish-List; APA Division 56 President Talks Psychedelics; Compass’ PTSD Study Published; Cybin Ousts Drysdale

PTSF81 – Somatics, Reframing Trauma, and the 7 Lens Approach, with...

MindMed Joins Clinical Trials Transformation Initiative

The Therapeutic Effects of Psychedelics: 2A or Not 2A?-Part 2

PharmaTher Granted FDA Orphan Drug Designation For Ketamine To Treat Complex...

Mindset Pharma Expands Benchmarking Data for First Generation Psychedelics Through the...

Levitee Labs Appoints Dr. Mohammed Mosli as Chief People Officer of...

MYND Diagnostics Inc. Announces Participation in a Monash University (Australia) Proposal...

Numinus Upgrades Psychedelics Lab to Increase Research Service Capabilities

PT266 – Jerry B. Brown, Ph.D. – Psychedelics: Past, Present, and...

atai Life Sciences announces the launch of PsyProtix, to develop a...

1...208209210...296Page 209 of 296

EDITOR PICKS

Q3’25 Psychedelic Drug Development Pipeline: Bullseye Charts

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

August 2025 Psychedelic Patent Update

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    ©